IFNA1 and hereditary clear cell renal cell carcinoma: Numerous cytokines have been validated for use in the treatment of cancer, some of which include IL-2 for the treatment of metastatic melanoma and renal cell carcinoma, in addition to IFN as an adjuvant therapy for stage III melanoma (Lee & Margolin, 2011).